CRISPR (CRSP) Director Ali Behbahani Exercises Options, Sells Shares

What Happened
Ali Behbahani, a director of CRISPR Therapeutics (CRSP), exercised 30,000 stock options on 2026-09-17 at $14.00 per share (cost $420,000) and, the same day, sold 13,679 common shares in the open market for a weighted average price of $57.09, generating proceeds of about $780,935. The Form 4 also reports a derivative disposition of 30,000 shares at a $0.00 price (see footnote F3 regarding the original option grant).

Key Details

• Transaction date: 2026-09-17; Form 4 filed 2026-09-21 (filed within the required 2 business days).
• Exercise: 30,000 shares exercised at $14.00 per share (total $420,000).
• Sale: 13,679 shares sold at a weighted average price of $57.09 (proceeds ≈ $780,935). Sales prices ranged from $56.97 to $57.43 (F1).
• Derivative line: 30,000 shares reported as disposed at $0.00 (derivative reporting; see F3).
• Beneficial ownership note: Behbahani is trustee of The Ali Behbahani Revocable Trust, which is the direct owner; he disclaims beneficial ownership for shares in which he has no pecuniary interest (F2).
• Shares owned after transaction: not stated in the provided filing excerpt.

Context

• This filing shows an option exercise combined with an immediate partial sale of shares the same day. That pattern is common (e.g., to cover exercise cost, taxes, or to take gains) but the filing itself does not state motivation.
• Footnote F3 indicates the exercised options were from a 2016 grant (30,000 shares, vesting schedule noted). Footnote F1 explains the sale price is a weighted average across multiple trades.
• The activity was reported promptly (filed on the next allowable business day).